Meeker added, “In addition, we continue to advance our MC4R agonism pipeline with upcoming data readouts from ongoing trials of setmelanotide in Prader-Willi syndrome and our weekly injectable, RM-718, in acquired HO. Our ongoing global commercial efforts and clinical development pipeline position Rhythm to achieve long-term, sustained growth.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
- RYTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity
- Rhythm Pharmaceuticals price target raised to $136 from $130 at RBC Capital
- Rhythm Pharmaceuticals appoints Popovits to board of directors